Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980534 | 0.78 | PRMT5 (0.54) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL3978671 | 0.78 | PRMT5 (0.54) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL29712359 | 0.78 | PRMT5 (0.54) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL3978681 | 0.78 | PRMT5 (0.54) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL19503944 | 0.73 | SLC28A1 (0.60) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL25566624 | 0.73 | SLC28A1 (0.60) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL19503939 | 0.73 | P2RY1 (0.61) | AHCY | |
| SCHEMBL10652076 | 0.70 | PI4K2A (0.60) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL12149495 | 0.70 | AHCY (0.86) | AHCYADORA2BSLC28A1SLC28A2 | |
| SCHEMBL24673464 | 0.70 | AHCY (0.59) | AHCYADORA2BSLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | AHCY 668/4885ADORA2B 30/4885SLC28A1 37/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | AHCY 741/4885ADORA2B 29/4885SLC28A1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.